Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Respiratory Disease Vaccine Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The respiratory disease vaccine market has shown marginal expansion over recent years. Its size is expected to increase from $70.03 billion in 2025 to $71.36 billion in 2026, progressing at a compound annual growth rate (CAGR) of 1.9%. This historical growth can be attributed to several factors, including the high prevalence of respiratory infections, the limited availability of effective vaccines, government-led immunization programs, breakthroughs in monoclonal antibody research, and a growing awareness surrounding respiratory health.
The respiratory disease vaccine market is projected to experience consistent expansion over the upcoming years. It will grow to $81 billion in 2030 at a compound annual growth rate (CAGR) of 3.2%. This anticipated growth during the forecast period is due to factors such as a rising need for universal vaccines, breakthroughs in mRNA and viral vector vaccine technologies, improvements in cold-chain logistics, an increase in public-private collaborations for vaccine delivery, and an emphasis on preparing for pandemics and ensuring quick responses. Key developments expected during this timeframe involve the creation of advanced respiratory vaccines, a heightened emphasis on vaccinating children and the elderly, the broadening of immunization initiatives in developing economies, the emergence of combination vaccines offering protection against multiple pathogens, and the implementation of swift vaccine development and deployment systems.
Get A Free Sample Report With In-Depth Market Insights:
Respiratory Disease Vaccine Market Growth Factors Behind Sustained Expansion
The increasing occurrence of tuberculosis (TB) is projected to boost the expansion of the respiratory disease vaccine market in the future. As an infectious respiratory ailment stemming from Mycobacterium tuberculosis, Tuberculosis mainly impacts the lungs and constitutes a considerable global health threat. Factors such as deteriorated healthcare systems, postponed diagnoses, and wider transmission patterns are driving the surge in TB cases, collectively intensifying the disease burden. Respiratory disease vaccines are essential for alleviating TB-related risks by lowering infection rates, constraining transmission, and bolstering worldwide prevention initiatives. A notable example comes from March 2024, where the Centers for Disease Control and Prevention, a US-based government agency, reported an increase in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, indicating a rise of 1,295 cases. Consequently, the escalating incidence of tuberculosis is propelling the growth of the respiratory disease vaccine market.
Respiratory Disease Vaccine Market Segment Analysis And Revenue Potential
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine
Respiratory Disease Vaccine Market Industry Trends Fueling Future Revenue Growth
Leading companies engaged in the respiratory disease vaccine market are focusing on developing innovative products to improve their effectiveness and deliver enhanced solutions for averting and addressing respiratory disease infections. For example, in May 2023, Pfizer Inc., a US-based pharmaceutical company, obtained Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, specifically for preventing lower respiratory tract disease induced by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine comprising a pair of preF proteins engineered to maximize immunity against RSV A and B varieties, and its safety and productivity have been clinically established.
Respiratory Disease Vaccine Market Key Players Shaping Industry Direction
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
View The Full Respiratory Disease Vaccine Market Report:
Respiratory Disease Vaccine Market Top Region: Where Does Most Revenue Come From?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
